Fig. 4: AT56 treatment promoted the ferroptosis process in PTCL cells. | British Journal of Cancer

Fig. 4: AT56 treatment promoted the ferroptosis process in PTCL cells.

From: Targeting PTGDS Promotes ferroptosis in peripheral T cell lymphoma through regulating HMOX1-mediated iron metabolism

Fig. 4

a Analysis of differentially expressed proteins based on TMT-mass spectrometry showed the potential regulatory role of AT56 treatment on ferroptosis in PTCL. b AT56 treatment for 36 h increased the expression of PTGS2 in PTCL cells, classic biomarker of ferroptosis. c AT56 enhanced the inhibitory effect of Erastin and Sorafenib on cell proliferation at 36 h. d, e AT56 treatment for 36 h significantly promoted the Erastin- and Sorafenib-induced accumulation of lipid ROS. f–h Fer-1 treatment for 36 h partly reversed AT56-induced cell proliferation inhibition and lipid ROS accumulation in PTCL cells. i–k The combination of AT56 and Sorafenib significantly inhibited tumor growth in PTCL mouse model. Data are shown as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.

Back to article page